An evaluation of anti-tumor effect and toxicity of PEGylated ursolic acid liposomes
Source abstract
Abstract
Therapy of solid tumors mediated by nano-drug delivery has attracted considerable interest. In our previous study, ursolic acid (UA) was successfully encapsulated into PEGylated liposomes. The study aimed to evaluate the tumor inhibition effect and cytotoxicity of the PEGylated UA liposomes by U14 cervical carcinoma-bearing mice. The liposomes were spherical particles with mean particle diameters of 127.2 nm. The tumor inhibition rate of PEGylated UA liposomes was 53.60 % on U14 cervical carcinoma-bearing mice, which was greater than those of the UA solution (18.25 %) and traditional UA liposome groups (40.75 %). The tumor cells apoptosis rate of PEGylated UA liposomes was 25.81 %, which was significantly higher than that of the traditional UA liposomes (13.37 %). Moreover, the kidney and liver did not emerge the pathological changes in UA therapeutic mice by histopathological analysis, while there were significant differences on tumor tissues among three UA formulation groups. The PEGylated UA liposomes exhibited higher anti-tumor activity and lower cytotoxicity, and the main reason was that the coating PEG layer improved UA liposome properties, such as enhancing the stability of liposomes, promoting the effect of slow release, and prolonging the time of blood circulation. This may shed light on the development of PEGylated nano-vehicles.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Natural product bioactivities and synthesis · Biological Activity of Diterpenoids and Biflavonoids · Bioactive Compounds and Antitumor Agents
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Al-Ahmady ZS, Scudamore CL, Kostarelos K (2015) Triggered doxorubicin release in solid tumors from thermosensitive liposome-peptide hybrids: critical parameters and therapeutic efficacy. Int J Cancer 137:731–743. doi: 10.1002/ijc.2943010.1002/ijc.29430 ↗
2. Allen TM (1994a) Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15:215–22010.1016/0165-6147(94)90314-X ↗
3. Allen TM (1994b) The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv Drug Deliv Rev 13:285–30910.1016/0169-409X(94)90016-7 ↗
4. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K (2005) Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem 16:122–13010.1021/bc0498166 ↗
5. Blume G, Cevc G, Crommelin M, Bakker-Woudenberg I, Kluft C, Storm G (1993) Specific targeting with poly (ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochimica et Biophysica Acta (BBA)-Biomembranes 1149:180–18410.1016/0005-2736(93)90039-3 ↗
6. Chan K (2003) Some aspects of toxic contaminants in herbal medicines. Chemosphere 52:1361–1371. doi: 10.1016/s0045-6535(03)00471-510.1016/S0045-6535(03)00471-5 ↗
7. Choi CHJ, Zuckerman JE, Paul W, Davis ME (2011) Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci USA 108:6656–666110.1073/pnas.1103573108 ↗
8. Dong R, Hao J (2010) Complex fluids of poly (oxyethylene) monoalkyl ether nonionic surfactants. Chem Rev 110:4978–502210.1021/cr9003743 ↗
9. He C, Hu Y, Yin L, Tang C, Yin C (2010) Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31:3657–366610.1016/j.biomaterials.2010.01.065 ↗
10. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1:297–31510.2217/17435889.1.3.297 ↗
11. Johnson LL et al (1993) Chemical contaminants and hepatic lesions in winter flounder (Pleuronectes americanus) from the northeast coast of the United States. Environ Sci Technol 27:2759–2771. doi: 10.1021/es00049a01510.1021/es00049a015 ↗
12. Kaszuba M, McKnight D, Connah MT, McNeil-Watson FK, Nobbmann U (2007) Measuring sub nanometre sizes using dynamic light scattering. J Nanopart Res 10:823–829. doi: 10.1007/s11051-007-9317-410.1007/s11051-007-9317-4 ↗
13. Kim ES, Moon A (2015) Ursolic acid inhibits the invasive phenotype of SNU-484 human gastric cancer cells. Oncol Lett 9:897–902. doi: 10.3892/ol.2014.273510.3892/ol.2014.2735 ↗
14. Kiran MS, Viji RI, Sameer Kumar VB, Sudhakaran PR (2008) Modulation of angiogenic factors by ursolic acid. Biochem Biophys Res Commun 371:556–560. doi: 10.1016/j.bbrc.2008.04.10810.1016/j.bbrc.2008.04.108 ↗
15. Kshirsagar N (2000) Drug delivery systems. Indian J Pharmacol 32:S54–S61
16. Lasic D, Martin F, Gabizon A, Huang S, Papahadjopoulos D (1991) Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochimica et Biophysica Acta (BBA)-Biomembranes 1070:187–19210.1016/0005-2736(91)90162-2 ↗
17. Lee RJ, Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198–320410.1016/S0021-9258(17)41848-5 ↗
18. Lee A-W et al (2010) Ursolic acid induces allograft inflammatory factor-1 expression via a nitric oxide-related mechanism and increases neovascularization. J Agric Food Chem 58:12941–12949. doi: 10.1021/jf103265x10.1021/jf103265x ↗
19. Li SD, Huang L (2010) Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 145:178–181. doi: 10.1016/j.jconrel.2010.03.01610.1016/j.jconrel.2010.03.016 ↗
20. Lin AY, Wang XH, Lee WN (2013) Phototransformation determines the fate of 5-fluorouracil and cyclophosphamide in natural surface waters. Environ Sci Technol 47:4104–4112. doi: 10.1021/es304976q10.1021/es304976q ↗
21. Liu J (1995) Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49:57–68. doi: 10.1016/0378-8741(95)90032-210.1016/0378-8741(95)90032-2 ↗
22. Liu Y, Fang J, Kim YJ, Wong MK, Wang P (2014) Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm 11:1651–1661. doi: 10.1021/mp500037310.1021/mp5000373 ↗
23. Liu Y, He M, Niu M, Zhao Y, Zhu Y, Li Z, Feng N (2015) Delivery of vincristine sulfate-conjugated gold nanoparticles using liposomes: a light-responsive nanocarrier with enhanced antitumor efficiency. Int J Nanomedicine 10:3081–3095. doi: 10.2147/IJN.S79550
24. Lopes SC, Novais MV, Ferreira DS, Braga FC, Magalhaes-Paniago R, Malachias A, Oliveira MC (2014) Ursolic acid incorporation does not prevent the formation of a non-lamellar phase in pH-sensitive and long-circulating liposomes. Langmuir 30:15083–15090. doi: 10.1021/la502977j10.1021/la502977j ↗
25. Ma L, Kohli M, Smith A (2013) Nanoparticles for combination drug therapy. ACS Nano 7:9518–952510.1021/nn405674m ↗
26. Maruyama K (2011) Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 63:161–16910.1016/j.addr.2010.09.003 ↗
27. Moghimi SM, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463–478. doi: 10.1016/s0163-7827(03)00033-x10.1016/S0163-7827(03)00033-X ↗
28. Murali VP, Kuttan G (2015) Enhancement of cancer chemotherapeutic efficacy of cyclophosphamide by Curculigo orchioides Gaertn and its ameliorative effects on cyclophosphamide-induced oxidative stress. Integr Cancer Ther 14:172–183. doi: 10.1177/153473541456442410.1177/1534735414564424 ↗
29. Nakash O et al (2014) Comorbidity of common mental disorders with cancer and their treatment gap: findings from the World Mental Health Surveys. Psycho-oncology 23:40–51. doi: 10.1002/pon.337210.1002/pon.3372 ↗
30. Onyesom I, Lamprou DA, Sygellou L, Owusu-Ware SK, Antonijevic M, Chowdhry BZ, Douroumis D (2013) Sirolimus encapsulated liposomes for cancer therapy: physicochemical and mechanical characterization of sirolimus distribution within liposome bilayers. Mol Pharm 10:4281–4293. doi: 10.1021/mp400362v10.1021/mp400362v ↗
31. Patro NM, Devi K, Pai RS, Suresh S (2013) Evaluation of bioavailability, efficacy, and safety profile of doxorubicin-loaded solid lipid nanoparticles. J Nanopart Res. doi: 10.1007/s11051-013-2124-1
32. QiLiang H, Shan J, XueJun W, LiShan X (2011) Effects of proanthocyanidin from pine needles on SOD activity, MDA content in serum and viscera index of mice. Med Plant 2(43–44):46
33. Ronald AFPD (1997) An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17:146S–154S
34. Ruysschaert T, Paquereau L, Winterhalter M, Fournier D (2006) Stabilization of liposomes through enzymatic polymerization of DNA. Nano Lett 6:2755–275710.1021/nl061724x ↗
35. Sette A, Spadavecchia J, Landoulsi J, Casale S, Haye B, Crociani O, Arcangeli A (2013) Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiO nanoparticles for targeting pancreatic ductal adenocarcinoma cells. J Nanopart Res 15:2111. doi: 10.1007/s11051-013-2111-610.1007/s11051-013-2111-6 ↗
36. Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G, Bishayee A (2013) Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. Biochem Pharmacol 85:1579–1587. doi: 10.1016/j.bcp.2013.03.00610.1016/j.bcp.2013.03.006 ↗
37. Sriwongsitanont S, Ueno M (2002) Physicochemical properties of PEG-grafted liposomes. Chem Pharm Bull 50:1238–124410.1248/cpb.50.1238 ↗
38. Stepniewski M et al (2011) Study of PEGylated lipid layers as a model for PEGylated liposome surfaces: molecular dynamics simulation and Langmuir monolayer studies. Langmuir 27:7788–7798. doi: 10.1021/la200003n10.1021/la200003n ↗
39. Sun C, Wang J, Liu J, Qiu L, Zhang W, Zhang L (2013) Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. AAPS PharmSciTech 14:332–338. doi: 10.1208/s12249-013-9924-610.1208/s12249-013-9924-6 ↗
40. Uppal R, Caravan P (2010) Targeted probes for cardiovascular MRI. Future Med Chem 2:451–47010.4155/fmc.09.154 ↗
41. Voinea M, Simionescu M (2002) Designing of ‘intelligent’ liposomes for efficient delivery of drugs. J Cell Mol Med 6:465–47410.1111/j.1582-4934.2002.tb00450.x ↗
42. Wang B, He X, Zhang Z, Zhao Y, Feng W (2012) Metabolism of nanomaterials in vivo: blood circulation and organ clearance. Acc Chem Res 46:761–76910.1021/ar2003336 ↗
43. Wenjuan L, Shaoping N, Yi C, Yuanxing W, Chang L, Mingyong X (2011) Enhancement of cyclophosphamide-induced antitumor effect by a novel polysaccharide from Ganoderma atrum in sarcoma 180-bearing mice. J Agric Food Chem 59:3707–371610.1021/jf1049497 ↗
44. Yang G, Yang T, Zhang W, Lu M, Ma X, Xiang G (2014) In vitro and in vivo antitumor effects of folate-targeted ursolic acid stealth liposome. J Agric Food Chem 62:2207–2215. doi: 10.1021/jf405675g10.1021/jf405675g ↗
45. Zhao T et al (2015) Self-assembly and cytotoxicity study of PEG-modified ursolic acid liposomes. Mater Sci Eng 53:196–203. doi: 10.1016/j.msec.2015.04.02210.1016/j.msec.2015.04.022 ↗